Hamideh Aghajani-Lazarjani

  • Citations Per Year
Learn More
BACKGROUND Recombinant monoclonal antibodies have been marketed in last three decades as the major therapeutic proteins against different cancers. However choosing a proper medium and supplements to reach the high expression is a challenging step. Despite of commercial serum free and chemically defined media, there are still numerous researches seeking the(More)
  • 1